BRRGF:OTC-BerGenBio ASA (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 3.52

Change

-0.36 (-9.28)%

Market Cap

USD 0.31B

Volume

500.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.95 (-1.33%)

USD164.04B 29.07 2.82
CMXHF CSL Limited

-4.95 (-2.33%)

USD96.74B 36.41 25.41
SBHMY Sino Biopharmaceutical Limited

-0.46 (-2.00%)

USD22.68B 35.23 3.07
SBMFF Sino Biopharmaceutical Limited

N/A

USD22.19B 36.36 3.67
GNMSF Genmab A/S

-14.20 (-4.20%)

USD21.85B 94.33 3.17
UCBJY UCB SA

-2.02 (-3.95%)

USD19.23B 18.93 16.14
UCBJF UCB SA

-9.50 (-8.89%)

USD19.21B 19.79 16.14
PPTDF PeptiDream Inc

N/A

USD5.99B 260.99 1.82
ABCZF Abcam plc

-0.40 (-1.77%)

USD4.99B 56.77 131.20
GENSF Genus plc

N/A

USD4.75B 65.57 53.60

ETFs Containing BRRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.66% 13% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.66% 12% F 14% F
Trailing 12 Months  
Capital Gain 120.00% 61% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.00% 61% D- 73% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 16.03% 49% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.03% 48% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 75.45% 51% F 35% F
Risk Adjusted Return 21.24% 52% F 53% F
Market Capitalization 0.31B 81% B- 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.84 65% D 31% F
Price / Cash Flow Ratio -1.32 38% F 66% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -57.76% 45% F 17% F
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets -32.36% 57% F 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.66 22% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.